Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer.
Lerner SP, Tangen C, Svatek RS, Daneshmand S, Pohar KS, Skinner E, Schuckman A, Sagalowsky AI, Smith ND, Kamat AM, Kassouf W, Plets M, Bangs R, Koppie TM, Alva A, La Rosa FG, Pal SK, Kibel AS, Canter DJ, Thompson IM Jr; SWOG S1011 Trial Investigators. Lerner SP, et al. Among authors: plets m. N Engl J Med. 2024 Oct 3;391(13):1206-1216. doi: 10.1056/NEJMoa2401497. N Engl J Med. 2024. PMID: 39589370 Free PMC article. Clinical Trial.
Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216.
Swami U, Jo Y, Narang A, Plets M, Hage Chehade C, Gebrael G, Gupta S, Myint Z, Tangen C, Lara PN Jr, Thompson IM Jr, Hussain MHA, Dorff TB, Lerner SP, Agarwal N. Swami U, et al. Among authors: plets m. Eur Urol Oncol. 2024 Nov 8:S2588-9311(24)00241-4. doi: 10.1016/j.euo.2024.10.013. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39521639
Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski JK, Ingles S, Triche TJ, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, Lara PN Jr, Hussain MHA, Quinn DI, Dorff TB, Lerner SP, Thompson I Jr, Agarwal N. Goldkorn A, et al. Among authors: plets m. JAMA Netw Open. 2024 Oct 1;7(10):e2437871. doi: 10.1001/jamanetworkopen.2024.37871. JAMA Netw Open. 2024. PMID: 39374015 Free PMC article. Clinical Trial.
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma.
Barata P, Tangen C, Plets M, Thompson IM Jr, Narayan V, George DJ, Heng DYC, Shuch B, Stein M, Gulati S, Tretiakova M, Tripathi A, Bjarnason GA, Humphrey P, Adeniran A, Vaishampayan U, Alva A, Zhang T, Cole S, Lara PN Jr, Lerner SP, Balzer-Haas N, Pal SK. Barata P, et al. Among authors: plets m. J Clin Oncol. 2024 Nov 20;42(33):3911-3916. doi: 10.1200/JCO.24.00767. Epub 2024 Sep 10. J Clin Oncol. 2024. PMID: 39255440 Free PMC article. Clinical Trial.
Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial.
Plimack ER, Tangen C, Plets M, Kokate R, Xiu J, Nabhan C, Ross EA, Grundy E, Choi W, Dinney CPN, Lee IC, Fong M, Scott Lucia M, Daneshmand S, Theodorescu D, Goldkorn A, Lerner SP, Flaig TW, McConkey DJ. Plimack ER, et al. Among authors: plets m. Eur Urol. 2024 Oct;86(4):297-300. doi: 10.1016/j.eururo.2024.06.018. Epub 2024 Jul 14. Eur Urol. 2024. PMID: 39003201
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial.
Gebrael G, Jo Y, Swami U, Plets M, Hage Chehade C, Narang A, Gupta S, Myint ZW, Sayegh N, Tangen CM, Hussain M, Dorff T, Lara PN Jr, Lerner SP, Thompson I, Agarwal N. Gebrael G, et al. Among authors: plets m. JAMA Netw Open. 2024 Jul 1;7(7):e2419966. doi: 10.1001/jamanetworkopen.2024.19966. JAMA Netw Open. 2024. PMID: 38980676 Free PMC article. Clinical Trial.
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial.
Lara PN Jr, Tangen C, Heath EI, Gulati S, Stein MN, Meng M, Alva AS, Pal SK, Puzanov I, Clark JI, Choueiri TK, Agarwal N, Uzzo R, Haas NB, Synold TW, Plets M, Vaishampayan UN, Shuch BM, Lerner S, Thompson IM Jr, Ryan CW. Lara PN Jr, et al. Among authors: plets m. Eur Urol. 2024 Sep;86(3):258-264. doi: 10.1016/j.eururo.2024.05.012. Epub 2024 May 29. Eur Urol. 2024. PMID: 38811313 Clinical Trial.
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
Lerner SP, McConkey DJ, Tangen CM, Meeks JJ, Flaig TW, Hua X, Daneshmand S, Alva AS, Lucia MS, Theodorescu D, Goldkorn A, Milowsky MI, Choi W, Bangs R, Gustafson DL, Plets M, Thompson IM Jr. Lerner SP, et al. Among authors: plets m. Clin Cancer Res. 2024 Jan 17;30(2):444-449. doi: 10.1158/1078-0432.CCR-23-0602. Clin Cancer Res. 2024. PMID: 37966367 Free PMC article. Clinical Trial.
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia.
Patel SP, Othus M, Chae YK, Dennis MJ, Gordon S, Mutch D, Samlowski W, Robinson WRR, Sharon E, Ryan C, Lopez G, Plets M, Blanke C, Kurzrock R. Patel SP, et al. Among authors: plets m. Clin Cancer Res. 2024 Jan 5;30(1):33-38. doi: 10.1158/1078-0432.CCR-23-2293. Clin Cancer Res. 2024. PMID: 37882676 Free PMC article. Clinical Trial.
32 results